文献速递浆细胞疾病

HDAC3调控多发性骨髓瘤中DNMT1的表达:治疗意义

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
PubMed 文献 · Leukemia · 2017-05-11

本研究探讨HDAC3抑制下调DNMT1表达并抑制多发性骨髓瘤(MM)细胞增殖的机制,发现HDAC3抑制通过降解c-Myc蛋白及诱导DNMT1高乙酰化降低DNMT1稳定性,HDAC3抑制剂BG45与DNMT1抑制剂5-氮杂胞苷(AZA)联用协同下调DNMT1、抑制生长并诱导凋亡,并在小鼠异种移植模型中证实疗效。

要点

  • 敲低HDAC3(而非HDAC1或HDAC2)及BG45可下调DNMT1表达,介导MM细胞增殖受抑。
  • HDAC3抑制通过降解c-Myc蛋白及诱导DNMT1高乙酰化降低DNMT1蛋白稳定性。
  • BG45与AZA联用协同下调DNMT1、抑制生长并诱导凋亡,小鼠异种移植模型证实疗效。

核心结论

  • 研究结果为HDAC3抑制剂联合DNMT1抑制剂改善MM患者预后提供了依据。

研究设计与样本

  • 研究采用基因敲低与选择性抑制剂BG45处理MM细胞,并在MM细胞系、患者MM细胞及小鼠异种移植MM模型中验证。

主要发现

  • 敲低HDAC3(而非HDAC1或HDAC2)以及BG45处理均下调DNMT1表达,介导MM细胞增殖受抑。
  • DNMT1表达受c-Myc调控,HDAC3抑制触发c-Myc蛋白降解。
  • HDAC3抑制导致DNMT1高乙酰化,从而降低DNMT1蛋白稳定性。
  • BG45与AZA联用协同下调DNMT1、抑制生长并诱导凋亡,在MM细胞系和患者MM细胞中均观察到。
  • 该联合治疗疗效在小鼠异种移植MM模型中得到证实。

临床怎么用

  • 作者认为,研究结果为HDAC3抑制剂联合DNMT1抑制剂改善MM患者预后提供了依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Epigenetic signaling pathways are implicated in tumorigenesis and therefore histone deacetylases (HDACs) represent novel therapeutic targets for cancers, including multiple myeloma (MM). Although non-selective HDAC inhibitors show anti-MM activities, unfavorable side effects limit their clinical efficacy. Isoform- and/or class-selective HDAC inhibition offers the possibility to maintain clinical activity while avoiding adverse events attendant to broad non-selective HDAC inhibition. We have previously reported that HDAC3 inhibition, either by genetic knockdown or selective inhibitor BG45, abrogates MM cell proliferation. Here we show that knockdown of HDAC3, but not HDAC1 or HDAC2, as well as BG45, downregulate expression of DNA methyltransferase 1 (DNMT1) mediating MM cell proliferation. DNMT1 expression is regulated by c-Myc, and HDAC3 inhibition triggers degradation of c-Myc protein. Moreover, HDAC3 inhibition results in hyperacetylation of DNMT1, thereby reducing the stability of DNMT1 protein. Combined inhibition of HDAC3 and DNMT1 with BG45 and DNMT1 inhibitor 5-azacytidine (AZA), respectively, triggers synergistic downregulation of DNMT1, growth inhibition and apoptosis in both MM cell lines and patient MM cells. Efficacy of this combination treatment is confirmed in a murine xenograft MM model. Our results therefore provide the rationale for combination treatment using HDAC3 inhibitor with DNMT1 inhibitor to improve patient outcome in MM.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Harada T, Ohguchi H, Grondin Y, et al. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications. Leukemia. 2017. PMID: 28490812. doi:10.1038/leu.2017.144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。